Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Sangamo Therapeutics stock in Canada | $10.78
Own Sangamo Therapeutics shares in just a few minutes.
Sangamo Therapeutics is a biotechnology business based in the US. Sangamo Therapeutics stocks (SGMO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.01 – an increase of 3.36% over the previous week. Sangamo Therapeutics employs 413 staff and has a trailing 12-month revenue of around $131.4 million.
How to buy Sangamo Therapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: SGMO in this case.
- Research Sangamo Therapeutics stocks. The platform should provide the latest information available.
- Buy your Sangamo Therapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Sangamo Therapeutics?
- Has coronavirus impacted Sangamo Therapeutics shares?
- Sangamo Therapeutics shares summary
- Compare share dealing platforms
- Is Sangamo Therapeutics stock a buy or sell?
- Sangamo Therapeutics performance over time
- Can I short Sangamo Therapeutics shares?
- Sangamo Therapeutics's financials
- How volatile are Sangamo Therapeutics shares?
- Does Sangamo Therapeutics pay a dividend?
- Other common questions
How has Coronavirus impacted Sangamo Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Sangamo Therapeutics's stock price has had significant positive movement.
Its last market close was $10.78, which is 30.98% up on its pre-crash value of $7.44 and 124.12% up on the lowest point reached during the March crash when the stocks fell as low as $4.81.
If you had bought $1,000 worth of Sangamo Therapeutics stocks at the start of February 2020, those stocks would have been worth $802.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,476.75.
Sangamo Therapeutics stock priceUse our graph to track the performance of SGMO stocks over time.
Sangamo Therapeutics stocks at a glance
|Latest market close||$10.78|
|52-week range||$9.14 - $19.43|
|50-day moving average||$11.1244|
|200-day moving average||$12.1917|
|Wall St. target price||$20.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.988|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Sangamo Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Sangamo Therapeutics price performance over time
|1 month (2021-06-28)||-11.28%|
|3 months (2021-04-28)||-12.57%|
Sangamo Therapeutics financials
|Revenue TTM||USD$131.4 million|
|Gross profit TTM||USD$-62,455,000|
|Return on assets TTM||-11.23%|
|Return on equity TTM||-28.73%|
|Market capitalisation||USD$1.5 billion|
TTM: trailing 12 months
How to short and sell Sangamo Therapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "SGMO.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 11.8 million Sangamo Therapeutics stocks held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 13.9% down from 13.7 million last month.
There are a few different ways that this level of interest in shorting Sangamo Therapeutics stocks can be evaluated.
Sangamo Therapeutics's "short interest ratio" (SIR)
Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics stocks currently shorted divided by the average quantity of Sangamo Therapeutics stocks traded daily (recently around 1.1 million). Sangamo Therapeutics's SIR currently stands at 10.65. In other words for every 100,000 Sangamo Therapeutics stocks traded daily on the market, roughly 10650 stocks are currently held short.
However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics stocks, or, against the total number of tradable Sangamo Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.08% of the outstanding stocks (for every 100,000 Sangamo Therapeutics stocks in existence, roughly 80 stocks are currently held short) or 0.0993% of the tradable stocks (for every 100,000 tradable Sangamo Therapeutics stocks, roughly 99 stocks are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Sangamo Therapeutics.
Find out more about how you can short Sangamo Therapeutics stock.
Sangamo Therapeutics stock dividends
We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Sangamo Therapeutics stock price volatility
Over the last 12 months, Sangamo Therapeutics's stocks have ranged in value from as little as $9.14 up to $19.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.7203. This would suggest that Sangamo Therapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sangamo Therapeutics overview
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Stocks similar to Sangamo Therapeutics
Sangamo Therapeutics in the news
First Week of September 17th Options Trading For Sangamo Therapeutics (SGMO)
What Kind Of Shareholders Own Sangamo Therapeutics, Inc. (NASDAQ:SGMO)?
Interesting SGMO Put And Call Options For February 2022
Frequently asked questions
More guides on Finder
Theme park stocks
Looking to buy into the amusement park industry? Check out this list of stocks.
How to buy Zevia PBC (ZVIA) stock in Canada
Everything we know about the Zevia PBC IPO, plus information on how to buy in.
How to buy Xponential Fitness (XPOF) stock in Canada
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
How to buy SOPHiA Genetics (SOPH) stock in Canada
Everything we know about the SOPHiA Genetics IPO, plus information on how to buy in.
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.